C-kit expression in pediatric solid tumors: a comparative immunohistochemical study

The American Journal of Surgical Pathology
Brandon E SmitheyD Ashley Hill

Abstract

The stem cell factor/c-kit tyrosine kinase receptor pathway has been shown to be important for tumor growth and progression in several cancers, including mast cell diseases, gastrointestinal stromal tumor, acute myeloid leukemia, small cell lung carcinoma, and Ewing sarcoma. Studies using the oral agent STI-571 (Gleevec, Novartis), an inhibitor of the tyrosine kinases bcr-abl, c-kit, and PDGFR, have shown significant responses in patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. With the aim of identifying additional groups of tumors that may use the stem cell factor/c-kit pathway and secondarily may be responsive to STI-571 treatment, this study surveyed 151 primary tumors from patients treated at St. Jude Children's Research Hospital for immunohistochemical expression of c-kit. Formalin-fixed, paraffin-embedded sections were stained with rabbit polyclonal anti-human c-kit (CD117, Dako) using standard avidin-biotin-peroxidase complex technique, antigen retrieval, and an automated stainer. Strong, diffuse staining for c-kit was seen in a proportion of synovial sarcomas, osteosarcomas, and Ewing sarcomas. Strong, diffuse staining was less common in neuroblastomas, Wilms' tumors, and rhabdomyosarcomas...Continue Reading

References

Jan 1, 1994·Advances in Immunology·S J GalliE N Geissler
Jan 13, 1998·Biochimica Et Biophysica Acta·K S Kolibaba, B J Druker
Oct 31, 1998·International Journal of Cancer. Journal International Du Cancer·L LanduzziP L Lollini
Jun 11, 1999·The American Journal of Pathology·Q TianC A Moskaluk
Mar 7, 2000·The American Journal of Pathology·M L LuxJ A Fletcher
Apr 27, 2000·Experimental Hematology·J M NelissenC G Figdor
May 29, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·M MiettinenJ Lasota
Oct 26, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·M MiettinenM Sarlomo-Rikala
Nov 14, 2000·The American Journal of Pathology·K IsozakiJ M Vanderwinden
Dec 6, 2000·The Journal of Surgical Research·C M ChenH J Harn
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers

❮ Previous
Next ❯

Citations

Feb 9, 2005·Brain Tumor Pathology·Tsuyoshi SuzukiToshiki Yoshimine
Aug 10, 2006·Cancer Chemotherapy and Pharmacology·Robert L FineGregory Halligan
Jun 22, 2010·Cancer Chemotherapy and Pharmacology·P A BaxterS M Blaney
Oct 19, 2010·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Hideshi SugiuraHideo Mugishima
Oct 22, 2008·Current Oncology Reports·Margaret E MacyLia Gore
Mar 11, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P Brown, D Small
Sep 1, 2004·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·C LangnerP Kornprat
Jun 9, 2005·Hematology/oncology Clinics of North America·Richard Carvajal, Paul Meyers
Jul 30, 2003·Cancer Genetics and Cytogenetics·Avery A Sandberg, Julia A Bridge
Jul 15, 2005·The New England Journal of Medicine·Daniela S Krause, Richard A Van Etten
May 10, 2003·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Paul C EdwardsRobert D Kelsch
Mar 1, 2003·Applied Immunohistochemistry & Molecular Morphology : AIMM·Muna SabahElaine Kay
Aug 6, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·Markku Miettinen, Jerzy Lasota
Aug 18, 2005·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Jose Antonio López-GuerreroAntonio Llombart-Bosch
Nov 8, 2005·Pathology International·Efsevia VakianiGovind Bhagat
Jun 27, 2007·The British Journal of Ophthalmology·Robert J BarryMiguel N Burnier
Oct 30, 2007·Journal of Clinical Pathology·Chris JonesKathy Pritchard-Jones
Mar 6, 2012·American Journal of Physiology. Lung Cellular and Molecular Physiology·Evgenia GerasimovskayaLaimute Taraseviciene-Stewart
Jul 20, 2007·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Sophie Collardeau-FrachonRaymonde Bouvier
Jul 11, 2006·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Gino R SomersMaria Zielenska
Oct 24, 2007·Cancer Investigation·Jeffrey M Skolnik, Peter C Adamson
May 28, 2004·Expert Opinion on Pharmacotherapy·Carlos Rodriguez-Galindo
Jun 24, 2010·Ultrastructural Pathology·Xiaoli XuTongzhen Chen
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Natacha Entz-WerléAnnie Babin-Boilletot
Oct 30, 2004·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mustafa AbbasM F Tungekar
Apr 2, 2013·Translational Oncology·Erin B DickersonStuart C Helfand
Oct 8, 2005·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Gino R SomersPaul S Thorner
Nov 18, 2004·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Susan Chilton-MacneillSylvain Baruchel
Jun 12, 2003·International Journal of Cancer. Journal International Du Cancer·Roberta VitaliCarlo Dominici
Mar 26, 2003·Medical and Pediatric Oncology·Carlos Rodriguez-GalindoAlberto S Pappo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of the National Cancer Institute
Melinda S MerchantCarol J Thiele
The American Journal of Surgical Pathology
Hala R MakhloufKamal G Ishak
© 2022 Meta ULC. All rights reserved